Zobrazeno 1 - 10
of 25
pro vyhledávání: '"Y. Velut"'
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Publikováno v:
Revue des Maladies Respiratoires. 40:124
Autor:
Véronique Duchatelle, Diane Damotte, Y. Velut, R. Herbst, Ludovic Fournel, G. Boulle, Scott A. Hammond, M. Wislez, Isabelle Cremer, Laure Gibault, Philippe Giraud, Hélène Blons, Marco Alifano, Audrey Mansuet-Lupo, A. Boni, Jean Trédaniel
Publikováno v:
European Journal of Cancer
European Journal of Cancer, Elsevier, 2020, 135, pp.221-229. ⟨10.1016/j.ejca.2020.04.040⟩
European Journal of Cancer, 2020, 135, pp.221-229. ⟨10.1016/j.ejca.2020.04.040⟩
European Journal of Cancer, Elsevier, 2020, 135, pp.221-229. ⟨10.1016/j.ejca.2020.04.040⟩
European Journal of Cancer, 2020, 135, pp.221-229. ⟨10.1016/j.ejca.2020.04.040⟩
Background Radiotherapy is a standard of care for locally advanced stage III N2 non–small-cell lung carcinoma (NSCLC) combined with surgery/chemotherapy. Radiotherapy is hypothesised to induce tumour immunogenic cell death, to release neoantigen re
Autor:
François Goldwasser, Diane Damotte, G. Boulle, M. Wislez, Karen Leroy, Y. Velut, Marco Alifano, Isabelle Cremer, Jérôme Biton, Audrey Lupo
Publikováno v:
Revue de Pneumologie Clinique. 74:339-350
Immune checkpoint inhibitors (ICI), targeting the PD1/PD-L1 axis has shown their efficacy in lung cancer but only in a restricted population of patients, thus it is mandatory to identify biomarkers predicting the clinical benefit. In this article we
Autor:
Diane Damotte, Marco Alifano, G. Boulle, P. Giraud, A. Boni, Y. Velut, Audrey Lupo, J. Trédaniel
Publikováno v:
Cancer/Radiothérapie. 22:688-693
Recent therapeutic advances in non-small cell lung cancer allow a better understanding of the interactions between the tumour and its direct immune environment. The identification of new immune biomarkers integrating both cell subpopulations and thei
Autor:
Marco Alifano, Bastien Rance, Audrey Mansuet-Lupo, Hélène Blons, M. Wislez, Jérôme Biton, Pierre Laurent-Puig, Jean-François Regnard, Ronald Herbst, Y. Velut, Makmoud Zarmaev, Marc Barritault, Aurélie Janet-Vendroux, Isabelle Cremer, Ludovic Fournel, Christine Le Hay, Diane Damotte
Publikováno v:
Journal of Thoracic Oncology
Journal of Thoracic Oncology, Lippincott, Williams & Wilkins, 2019, 14, pp.844-856. ⟨10.1016/j.jtho.2019.01.017⟩
Journal of Thoracic Oncology, Lippincott, Williams & Wilkins, 2019, 14, pp.844-856. ⟨10.1016/j.jtho.2019.01.017⟩
Introduction Multiple nodules in the lung are being diagnosed with an increasing frequency thanks to high-quality computed tomography imaging. In patients with lung cancer, this situation represents up to 10% of patients who have an operation. For cl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c9f64f0e5b5077fa6511fbf1b058399b
https://hal.archives-ouvertes.fr/hal-03486393/file/S1556086419300930.pdf
https://hal.archives-ouvertes.fr/hal-03486393/file/S1556086419300930.pdf
Autor:
Philippe Giraud, Diane Damotte, Scott A. Hammond, A. Boni, Y. Velut, M. Wislez, Laure Gibault, Jean Trédaniel, Marco Alifano, Audrey Lupo, Véronique Duchatelle, Isabelle Cremer, Ludovic Fournel, Geoffroy Boulle, Hélène Blons
Publikováno v:
Cancer Research. 80:4304-4304
Background: radiotherapy is a standard of care for locally advanced stage III (N2) non-small cell lung cancer (NSCLC) combined with surgery and/or chemotherapy. Radiotherapy is hypothesized to induce intra-tumoral immune infiltration via neoantigen r
Autor:
A, Lupo, M, Alifano, M, Wislez, G, Boulle, Y, Velut, J, Biton, I, Cremer, F, Goldwasser, K, Leroy, D, Damotte
Publikováno v:
Revue de pneumologie clinique. 74(5)
Immune checkpoint inhibitors (ICI), targeting the PD1/PD-L1 axis has shown their efficacy in lung cancer but only in a restricted population of patients, thus it is mandatory to identify biomarkers predicting the clinical benefit. In this article we
Publikováno v:
Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique. 22(6-7)
Recent therapeutic advances in non-small cell lung cancer allow a better understanding of the interactions between the tumour and its direct immune environment. The identification of new immune biomarkers integrating both cell subpopulations and thei